Application of compound SAICAR in preparation of product for improving skin aging

The compound SAICAR promotes COL17 expression in the skin, solving the risks and unknown components of existing anti-skin aging methods, and provides a safe, efficient, accurate and low-cost treatment for skin aging.

CN119074739APending Publication Date: 2024-12-06SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411221004.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing anti-skin aging methods such as surgery and skin care products have risks and unknown ingredients, and existing drugs have poor treatment for skin aging and are difficult to sustain.

Method used

The compound SAICAR promotes upregulation of COL17 expression in the skin, and forms pharmaceutical products that improve skin aging by combining with pharmaceutically acceptable carriers, including dosage forms such as injections and emulsions, with a SAICAR concentration of 1-100μM.

Benefits of technology

Promoting COL17 expression through SAICAR provides a safe, efficient and accurate anti-skin aging treatment method. Compared with surgical procedures, there are no surgical injuries, clear components, high efficiency, and cost advantages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074739A_ABST
    Figure CN119074739A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of anti-aging, and particularly discloses application of a compound SAICAR in preparation of a product for improving skin aging. The invention provides the application of the SAICAR as the medicine for promoting COL17 expression in the aged skin and resisting skin aging for the first time, and the SAICAR is applied to promote COL17 expression in the aged skin, so that the skin aging phenotype is improved. Compared with plastic surgery and cosmetic surgery and the like, the medicine provided by the invention has the advantages of no surgical injury, convenience in use and high safety; compared with the existing anti-skin-aging skin care product, the composition is definite, the treatment target is definite, and the efficiency is relatively high; and compared with the existing medicine, the compound has a remarkable advantage in cost and is relatively low in synthesis cost.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of anti-aging technology, and in particular to use of a compound SAICAR in preparing a product for improving skin aging. Background Art

[0002] Cells, tissues and organs in organisms will gradually age with age, causing the body to show overall aging of multiple systems, the most intuitive of which is skin aging. Skin aging is accompanied by obvious signs, such as thin and dry skin, fine wrinkles, decreased elasticity, pigmentation, etc. Skin aging not only affects appearance, but also has a multi-faceted and comprehensive impact on personal emotions, psychology, sociality, etc. Therefore, skin anti-aging treatment is of great significance to improving personal comprehensive happiness and quality of life.

[0003] Modern medicine's anti-aging skin methods mainly include surgical treatment and anti-aging skin care products. Surgical treatments such as plastic surgery can improve the appearance of skin aging to a certain extent, but as a surgical operation, it has a greater risk and may cause facial vascular nerve damage, resulting in infection, facial paralysis or local deformity. In addition, the existing anti-aging skin care products are mostly made of natural plant extracts, with complex and unclear ingredients. The unknown ingredients are easy to cause harm to the human body, not only with poor nourishing effects, but also with irritation to the skin. After discontinuation of use, the effect is difficult to continue and may even deteriorate rapidly. Therefore, these methods have not yet achieved ideal therapeutic effects.

[0004] Collagen type 17 (COL17) is a transmembrane protein that mediates the interaction between stem cells and surrounding cells and matrix in the skin, and plays an important role in regulating skin homeostasis and aging. The expression of COL17 in aged skin is significantly lower than that in young skin. Studies have shown that in aged mice over 24 months old, increasing the expression of COL17 can reverse skin aging phenotypes such as epidermal thinning and hair loss, indicating that upregulating COL17 expression is a promising anti-skin aging strategy. Therefore, if effective drugs can be found to target and upregulate COL17 expression in the skin, it will be possible to provide a precise and effective new method for anti-skin aging treatment. Summary of the invention

[0005] In order to solve the above problems, the present invention provides the use of the compound SAICAR in preparing a product for improving skin aging. 13 H 19 N4O 12 The general chemical structure of P) is as follows:

[0006]

[0007] Furthermore, the SAICAR achieves the effect of improving skin aging by promoting the expression of COL17 in the skin.

[0008] Further, the product comprises SAICAR and a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" means that when the carrier is properly administered to an animal or a human, they do not produce adverse, allergic or other adverse reactions. The pharmaceutically acceptable carrier can be selected from one or more of a diluent, a filler, a surfactant, an absorption promoter, a disintegrant, a wetting agent, a dispersant, and the like.

[0009] Furthermore, the concentration of SAICAR in the product is 1-100 μM.

[0010] Furthermore, the concentration of SAICAR in the product is 50 μM.

[0011] Furthermore, the dosage form of the product includes but is not limited to any one of injection, emulsion, tablet, powder, granule, gel, ointment, liposome, and oral solution.

[0012] The present invention also provides a pharmaceutical composition for improving skin aging, which contains SAICAR as an effective ingredient.

[0013] Furthermore, the pharmaceutical composition comprises SAICAR and a pharmaceutically acceptable carrier.

[0014] Furthermore, the concentration of SAICAR in the pharmaceutical composition is 1-100 μM.

[0015] The present invention has the following beneficial effects:

[0016] 1. The present invention promotes the expression of COL17 in aging skin by using SAICAR, thereby improving the skin aging phenotype and providing a precise and effective new method for anti-skin aging treatment.

[0017] 2. The present invention proposes for the first time the use of SAICAR as a drug for promoting COL17 expression in aging skin and anti-skin aging; compared with plastic surgery and cosmetic surgery, the drug involved in the present invention has no surgical damage, is easy to use, and has high safety; compared with existing anti-skin aging skin care products, the drug involved in the present invention has clear ingredients, clear therapeutic targets, and high efficiency.

[0018] 3. The drug product involved in the present invention has significant cost advantages over currently available drugs and has a lower synthesis cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 : Western blot experimental results in Example 1.

[0020] Figure 2 : The results of histological HE staining in Example 1. In the figure, the left side shows the appearance of the tissue after HE staining, and the right side shows the measurement data of dermal thickness. DETAILED DESCRIPTION

[0021] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0022] Example 1

[0023] 1. Experimental Materials

[0024] 1.1 The preparation method of SAICAR solution is as follows:

[0025] SAICAR was purchased from MCE (Cat. No. HY-126585) and dissolved in sterile water to prepare a 10 mM stock solution. In the in vivo experiment, physiological saline was added to prepare a 50 μM solution.

[0026] 2. Experimental Methods

[0027] 2.1 Establishment of mouse aging model and SAICAR injection

[0028] The experiment used 8-week-old mice as the young group and 12-month-old mice as the aged group. Self-control was used during treatment, divided into: control side (solvent control) and SAICAR side (50μM); the injection method was: subcutaneous injection of 100μL every other day, and continued injection for 1 month, and the skin with a diameter of 8mm at the injection site was collected and quickly frozen or immersed in 4% paraformaldehyde for subsequent experiments.

[0029] 2.2 Tissue sections and HE staining

[0030] Fresh tissues were fixed in 10% formalin solution for more than 24 hours, then embedded in paraffin and cut into 4 μm sections. The sections were dewaxed and hydrated, then stained with hematoxylin solution (Harris) and eosin solution, and observed under an upright microscope.

[0031] 2.3 Western blot

[0032] Add RIPA lysis buffer (containing 1% PMSF) to the tissue and lyse on ice for 30 minutes. Centrifuge to obtain the supernatant, add 4× protein SDS-PAGE loading buffer, and heat at 95°C. Use 10% SDS-PAGE gel for electrophoresis to separate proteins. Transfer to PVDF membrane. After transfer, block with 5% skim milk for 1 hour. Add primary antibody and incubate overnight at 4°C. Add peroxidase-conjugated secondary antibody the next day and incubate at room temperature for 1 hour. Add developer and use chemiluminescence imaging system for development.

[0033] 3. Experimental results

[0034] 3.1 SAICAR increases COL17 expression in aging skin

[0035] The skin aging process was simulated using mice aged 8 weeks and 12 months. After continuous injection of drugs into the aged skin for 1 month, samples were obtained and tissue proteins were extracted for WB detection. The results showed that compared with young mice, the expression of COL17 in the skin of aged mice was significantly reduced, while the expression level of COL17 was significantly increased after treatment with 50μM SAICAR ( Figure 1 ).

[0036] 3.2 SAICAR can increase dermal thickness and improve skin aging phenotype

[0037] After continuous injection of drugs for 1 month, samples were obtained for HE staining. The results showed that compared with young mice, the hair follicle density and dermal thickness of the aged mice were significantly reduced. After injection of 50μM SAICAR, the hair follicle density and dermal thickness of the aged mice were significantly increased, and the aging phenotype of the skin was significantly improved ( Figure 2 ).

[0038] This specific implementation is only an explanation of the present invention, not a limitation of the present invention. Any changes made by those skilled in the art after reading the specification of the present invention will be protected by the patent law as long as they are within the scope of the claims of the present invention.

Claims

1. Use of the compound SAICAR in preparing products for improving skin aging.

2. Use of the compound SAICAR according to claim 1 in preparing a product for improving skin aging, characterized in that: The SAICAR improves skin aging by promoting the expression of COL17 in the skin.

3. Use of the compound SAICAR according to claim 1 in preparing a product for improving skin aging, characterized in that: The product comprises SAICAR and a pharmaceutically acceptable carrier.

4. Use of the compound SAICAR according to claim 3 in preparing a product for improving skin aging, characterized in that: The concentration of SAICAR in the product is 1-100 μM.

5. Use of the compound SAICAR according to claim 4 in preparing a product for improving skin aging, characterized in that: The concentration of SAICAR in the product is 50 μM.

6. Use of the compound SAICAR according to claim 3 in preparing a product for improving skin aging, characterized in that: The pharmaceutically acceptable carrier is selected from one or more of a diluent, a filler, a surfactant, an absorption enhancer, a disintegrant, a wetting agent, and a dispersant.

7. Use of the compound SAICAR according to claim 3 in preparing a product for improving skin aging, characterized in that: The dosage form of the product is injection, emulsion, tablet, powder, granule, gel, ointment, liposome or oral solution.

8. A pharmaceutical composition for improving skin aging, characterized in that: Contains SAICAR as the active ingredient.

9. The pharmaceutical composition for improving skin aging according to claim 8, characterized in that: It comprises SAICAR and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition for improving skin aging according to claim 8, characterized in that: The concentration of SAICAR is 1-100 μM.